ImmuPharma plcLSE: IMM

2019 Annual General Meeting

· Issued by ImmuPharma PLC

On 6ix: 6ix.com/news/2019-annual-general-meeting

Watch ImmuPharma's latest callImmupharma (LSE:IMM) — Corporate Update · Replay · Mar 20Read the transcript of Immupharma (LSE:IMM) — Corporate Update
RNS Number : 6908D
Immupharma PLC
27 June 2019
 

                                                                                                                                                                      27 JUNE 2019

ImmuPharma PLC

("ImmuPharma" or the "Company")

2019 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

-Ends-

For further information please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 8974

+44 (0) 203 815 8880

+44 (0) 1483 413500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMUBOURKVANUAR

ImmuPharma plc on 6ix

Story so far

Earlier from ImmuPharma

Later from ImmuPharma

All ImmuPharma news releases